PARP inhibitors and stratified treatment of prostate cancer.
a Clinical Research Fellow in Medical Oncology , Guy's Hospital , London.
Anita
A
Lavery
b MRC Clinical Trials Unit , University College London , London , UK.
Clare
C
Gilson
c Consultant Medical Oncologist, Guy's Hospital , London.
Simon
S
Chowdhury
D000970:Antineoplastic Agents / Q000494:pharmacology*; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000494:pharmacology*; D011065:Poly(ADP-ribose) Polymerases / Q000187:drug effects / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015996:Survival Rate
D000970:Antineoplastic Agents; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases
BRCA1/2 mutation; Biomarker; PARP inhibitor; prostate cancer; stratification; targeted therapy